Literature DB >> 33386606

Temporal trends from 2005 to 2018 in deaths and cardiovascular events in subjects with newly diagnosed rheumatoid arthritis.

Giovanni Cioffi1,2, Marta Baviera3, Pierluca Colacioppo4, Mauro Tettamanti5, Ida Fortino6, Maria Carla Roncaglioni4.   

Abstract

Although rheumatoid arthritis (RA) is associated with an increased risk of death and cardiovascular (CV) disease, the excess of these risks is expected to have diminished over time, in more recent incident cohorts with RA. We analysed the risk of all-cause death, stroke, and myocardial infarction as primary outcomes and all CV events as secondary outcomes in RA subjects compared to the general population, from 2005 to 2018. The risk outcomes were also evaluated in relation to the time since RA diagnosis. We conducted a cohort study using linkable administrative healthcare databases of the Lombardy Region, Northern Italy. Analyses included subjects newly diagnosed RA subjects and a random sample of No-RA subjects. An adjusted Cox proportional hazard regression model was used to calculate hazard ratios and 95% CIs for all outcomes. The study population comprised 16,047 RA subjects and 500,000 without RA. The risks of dying (HR 1.22, 95% CI 1.15-1.30), stroke (HR 1.39, 95% CI 1.22-1.58), myocardial infarction (HR 2.00, 95% CI 1.78-2.26) were significantly higher in the RA cohort, as were those that for secondary outcomes. Differences between RA and No-RA already emerged during the first five years after diagnosis. Risk patterns remained statistically significant during the next 5 years or more. Subjects with RA still have a higher risk of death and worse CV outcomes than the general population, appearing early and not decreasing with time. Preventive interventions are urgently needed.
© 2021. Società Italiana di Medicina Interna (SIMI).

Entities:  

Keywords:  Cardiovascular disease; Death; Myocardial infarction; Rheumatoid arthritis; Stroke

Year:  2021        PMID: 33386606     DOI: 10.1007/s11739-020-02581-z

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  5 in total

1.  Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept.

Authors:  Elena Generali; Greta Carrara; Carlo Selmi; Suzanne M M Verstappen; Antonella Zambon; Alessandra Bortoluzzi; Ettore Silvagni; Carlo Alberto Scirè
Journal:  Clin Exp Rheumatol       Date:  2017-12-28       Impact factor: 4.473

2.  Trend in and predictors for cardiovascular mortality in patients with rheumatoid arthritis over a period of 15 years: a prospective cohort study.

Authors:  Joëlle van den Hoek; Leo D Roorda; Hendriek C Boshuizen; Gerard J Tijhuis; Joost Dekker; Geertrudis A van den Bos; Michael T Nurmohamed
Journal:  Clin Exp Rheumatol       Date:  2016-08-02       Impact factor: 4.473

3.  Validity of Diagnostic Codes for Acute Stroke in Administrative Databases: A Systematic Review.

Authors:  Natalie McCormick; Vidula Bhole; Diane Lacaille; J Antonio Avina-Zubieta
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

4.  A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case-control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology.

Authors:  Greta Carrara; Carlo A Scirè; Antonella Zambon; Marco A Cimmino; Carlo Cerra; Marta Caprioli; Giovanni Cagnotto; Federica Nicotra; Andrea Arfè; Simona Migliazza; Giovanni Corrao; Giovanni Minisola; Carlomaurizio Montecucco
Journal:  BMJ Open       Date:  2015-01-28       Impact factor: 2.692

5.  A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbria Data-Value Project.

Authors:  Francesco Cozzolino; Alessandro Montedori; Iosief Abraha; Paolo Eusebi; Chiara Grisci; Anna Julia Heymann; Guido Lombardo; Anna Mengoni; Massimiliano Orso; Giuseppe Ambrosio
Journal:  PLoS One       Date:  2019-07-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.